No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
CHMP Recommends Expanded Indications for Janssen’s Stelara®, Darzalex® & Tremfya®; AZ’s Imfinzi®; Daiichi’s Enhertu®; Roche’s Columvi®
At its February 2025 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended expanded therapeutic indications for 16 medicines, including the following six biopharmaceuticals.